Re: Collagenase Clostridium Histolyticum for the Treatment of Peyronie’s Disease: A Prospective Ital...
Re: Collagenase Clostridium Histolyticum for the Treatment of Peyronie’s Disease: A Prospective Italian Multicentric Study
About this item
Full title
Author / Creator
Capece, M , Cocci, A , Russo, G , Cito, G , Giubilei, G , Cacciamani, G , Garaffa, G , Falcone, M , Timpano, M , Tasso, G , Sessa, F , Campi, R , Di Maida, F , Cai, T , Morelli, G , Giammusso, B , Verze, P , Palmieri, A , Ralph, D , Mirone, V and Mondaini, N
Publisher
Ankara: Galenos Yayinevi Tic. Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Ankara: Galenos Yayinevi Tic. Ltd
Subjects
More information
Scope and Contents
Contents
Collagenase clostridium histolyticum (CCH) is the first licensed drug for the treatment of Peyronie’s diease and is indicated in
patients with palpable plaque and a curvature deformity of ≥30°.
Alternative Titles
Full title
Re: Collagenase Clostridium Histolyticum for the Treatment of Peyronie’s Disease: A Prospective Italian Multicentric Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_fa91fb8016224386b05c0ee0478bde19
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_fa91fb8016224386b05c0ee0478bde19
Other Identifiers
ISSN
2148-9580
E-ISSN
2148-9580
DOI
10.4274/jus.2019.06.006
